Fig. 1

Changes in the lymphocyte count (A) and neutrophil–lymphocyte count ratio (B) at baseline, after 4 weeks of dasatinib therapy, after 6 months of dasatinib therapy, and at the last follow-up. The follow-up durations were 12 (6‒76) months in the chronic kidney disease (CKD) group and 28 (7‒100) months in No CKD group, respectively. Solid circles with a solid line indicate the CKD group. Open circles with a dashed line indicate the No CKD group. *Difference between the groups, p = 0.020. ** Difference between the groups, p = 0.098